SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following news of strengthening its balance sheet by converting convertible notes, eliminating corporate-level indebtedness and potential equity overhang. This development has ignited fervent community discussion, with many anticipating a massive short squeeze due to the perceived low float and high short interest. However, others remain cautious, recalling the stock's history of extreme volatility and sharp price corrections, debating if this marks a significant rebound or another speculative cycle.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is generating significant buzz as its subsidiary is reported to be a prime contractor for a major border security initiative, fueling strong community discussion around its autonomous drone and counter-UAS capabilities. Investors are actively anticipating substantial growth, viewing the company as a key player in the expanding global defense sector, especially with broad tailwinds from increased military spending and drone technology adoption.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. (ACON) is gaining significant traction following its corporate outlook, highlighting triple-digit growth for its AI back pain platform, a debt-free balance sheet with substantial cash, and expanding commercial reach. The community is actively debating the stock's exceptionally low share float and high cash-per-share value, anticipating a potential short squeeze and sustained upward momentum. However, some market participants express caution regarding historical volatility and perceived manipulation as volume surges around key price points.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending after experiencing a multi-day pullback, with investors keenly debating whether the stock is ripe for a bounce due to oversold technicals. While many anticipate a rebound, others express caution, highlighting a perceived lack of immediate AI catalysts compared to peers and Apple's recent market capitalization shift behind Alphabet. This dynamic has created a split in community sentiment, ranging from aggressive dip-buying to continued bearishness.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive Inc. is actively trending following a significant partnership with Starlink, positioning the company as an authorized dealer and installer for SpaceX's high-speed in-flight connectivity on private jets. This development has fueled widespread community discussion around its potential to drive a substantial short squeeze and future price appreciation, though some traders note existing volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, confirming its sonelokimab therapy can proceed with a Biologics License Application for hidradenitis suppurativa without additional clinical trials. The community is actively discussing the potential for significant analyst price target upgrades and renewed buyout speculation, with many anticipating a substantial increase from current levels. Despite volatile trading, investors see this de-risked regulatory pathway as a strong catalyst for future appreciation, especially with an Investor Day announced for February.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to recently updated revenue guidance for DefenCath extending into 2026 and 2027, which has unfortunately overshadowed the release of strong real-world evidence data for the product and its ongoing diversification through the Melinta acquisition. The community is sharply divided, with many expressing deep disappointment and accusations of mismanagement, while others view the resulting market reaction as an overdone sell-off and a significant buying opportunity for the company's long-term potential.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics (SERV) is experiencing significant buzz following endorsements from NVIDIA CEO Jensen Huang and Wedbush analyst Dan Ives, coupled with reports that the Trump administration is considering an executive order to boost the robotics industry. The community is actively discussing the company's rapidly expanding autonomous delivery fleet and partnerships with Uber Eats and DoorDash, anticipating a potential short squeeze fueled by high short interest within the burgeoning physical AI sector.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending due to a significant strategic pivot, exiting unprofitable large EV programs while doubling down on hybrids and affordable future electric vehicles, a move analysts like Piper Sandler are upgrading as a path to improved profitability. This re-focus, alongside strong overall sales driven by trucks and SUVs, is sparking community discussion about Ford's pragmatic adaptation to market demand, with some anticipating potential short squeeze dynamics despite a substantial write-down related to its past EV investments.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is notably trending following a business update highlighting a record revenue quarter and anticipation of multiple upcoming FDA decisions for its Afrezza and FUROSCIX products. While investors are enthusiastic about future growth catalysts and M&A speculation, there's ongoing community debate regarding past stock performance and insider share transactions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Savara (NASDAQ:SVRA) Shares Down 5.1% - Should You Sell?

Savara (NASDAQ:SVRA) Trading Down 5.1% - What's Next...

Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December

Savara Inc. (NASDAQ:SVRA - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 20,185,493 shares, an increase of 33.1% from the...

Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA

Swedbank AB acquired a new stake in Savara Inc. (NASDAQ:SVRA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor...

What is HC Wainwright's Forecast for Savara FY2027 Earnings?

Savara Inc. (NASDAQ:SVRA - Free Report) - Investment analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Savara in a research note issued on Tuesday...

FY2029 Earnings Estimate for Savara Issued By HC Wainwright

Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at HC Wainwright increased their FY2029 earnings per share (EPS) estimates for shares of Savara in a note issued to investors on Tuesday...

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with...

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will present and host...

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the company, Marketbeat.com...

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a...

Savara (NASDAQ:SVRA) Reaches New 12-Month High - Here's What Happened

Savara (NASDAQ:SVRA) Hits New 52-Week High - Here's What Happened...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

SpaceX

Discord

OpenAI

Other - Comment Below

A few major private companies are being discussed as potential IPO candidates in 2026 — including SpaceX, Discord, Databricks, OpenAI, Anthropic, and Deel. IPO timelines can shift, but if one of these listings happens this year, which are you most excited to watch?

Which Potential 2026 IPO Are You Most Excited For?

SVRA
Savara Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SVRA News

SVRASavara Inc